APO Research
Talk to an analyst

APO RESEARCH · REPORT

FIC Dual-target Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global FIC Dual-target Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025193 pages

Choose your research edition.

Industry ResearchFIC Dual-target Drugs Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal FIC Dual-target Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal FIC Dual-target Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FIC Dual-target Drugs Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal FIC Dual-target Drugs Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global FIC Dual-target Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for FIC Dual-target Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for FIC Dual-target Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for FIC Dual-target Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for FIC Dual-target Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of FIC Dual-target Drugs include Agios, BMS, Boehringer Ingelheim, Dermavant Sciences, Genentech, Gilead, Immunocore, ImmunoGen and Mallinckrodt, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global FIC Dual-target Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of FIC Dual-target Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents FIC Dual-target Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the FIC Dual-target Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

FIC Dual-target Drugs Segment by Company

Agios

BMS

Boehringer Ingelheim

Dermavant Sciences

Genentech

Gilead

Immunocore

ImmunoGen

Mallinckrodt

Marinus

Phathom

Polarean lmaging

Pfizer

Eli Lilly

Roche

Merck

Novartis

Johnson & Johnson

Sanofi

FIC Dual-target Drugs Segment by Type

Polθ/PARP Targets

GPX4/CDK Targets

EZH2/HSP90 Targets

Others

FIC Dual-target Drugs Segment by Application

Hospital

Clinic

Other

FIC Dual-target Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FIC Dual-target Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FIC Dual-target Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FIC Dual-target Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the FIC Dual-target Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of FIC Dual-target Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of FIC Dual-target Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of FIC Dual-target Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. FIC Dual-target Drugs Industry Trends Table 2. FIC Dual-target Drugs Industry Drivers Table 3. FIC Dual-target Drugs Industry Opportunities and Challenges Table 4. FIC Dual-target Drugs Industry Restraints Table 5. Global FIC Dual-target Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global FIC Dual-target Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global FIC Dual-target Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global FIC Dual-target Drugs Sales Market Share by Manufacturers Table 9. Global FIC Dual-target Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global FIC Dual-target Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global FIC Dual-target Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global FIC Dual-target Drugs Manufacturers, Product Type & Application Table 13. Global FIC Dual-target Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global FIC Dual-target Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Polθ/PARP Targets Table 17. Major Manufacturers of GPX4/CDK Targets Table 18. Major Manufacturers of EZH2/HSP90 Targets Table 19. Major Manufacturers of Others Table 20. Global FIC Dual-target Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global FIC Dual-target Drugs Sales by Type (2021-2026) & (K Units) Table 22. Global FIC Dual-target Drugs Sales by Type (2027-2032) & (K Units) Table 23. Global FIC Dual-target Drugs Sales Market Share by Type (2021-2026) Table 24. Global FIC Dual-target Drugs Sales Market Share by Type (2027-2032) Table 25. Global FIC Dual-target Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global FIC Dual-target Drugs Revenue by Type (2021-2026) & (K Units) Table 27. Global FIC Dual-target Drugs Revenue by Type (2027-2032) & (K Units) Table 28. Global FIC Dual-target Drugs Revenue Market Share by Type (2021-2026) Table 29. Global FIC Dual-target Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Other Table 33. Global FIC Dual-target Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global FIC Dual-target Drugs Sales by Application (2021-2026) & (K Units) Table 35. Global FIC Dual-target Drugs Sales by Application (2027-2032) & (K Units) Table 36. Global FIC Dual-target Drugs Sales Market Share by Application (2021-2026) Table 37. Global FIC Dual-target Drugs Sales Market Share by Application (2027-2032) Table 38. Global FIC Dual-target Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global FIC Dual-target Drugs Revenue by Application (2021-2026) & (K Units) Table 40. Global FIC Dual-target Drugs Revenue by Application (2027-2032) & (K Units) Table 41. Global FIC Dual-target Drugs Revenue Market Share by Application (2021-2026) Table 42. Global FIC Dual-target Drugs Revenue Market Share by Application (2027-2032) Table 43. Global FIC Dual-target Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global FIC Dual-target Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global FIC Dual-target Drugs Sales Market Share by Region (2021-2026) Table 46. Global FIC Dual-target Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global FIC Dual-target Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America FIC Dual-target Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America FIC Dual-target Drugs Sales by Country (2021-2026) & (K Units) Table 50. North America FIC Dual-target Drugs Sales by Country (2027-2032) & (K Units) Table 51. Europe FIC Dual-target Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe FIC Dual-target Drugs Sales by Country (2021-2026) & (K Units) Table 53. Europe FIC Dual-target Drugs Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific FIC Dual-target Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific FIC Dual-target Drugs Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific FIC Dual-target Drugs Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa FIC Dual-target Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa FIC Dual-target Drugs Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa FIC Dual-target Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global FIC Dual-target Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global FIC Dual-target Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global FIC Dual-target Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global FIC Dual-target Drugs Revenue Market Share by Region (2021-2026) Table 64. Global FIC Dual-target Drugs Revenue Market Share by Region (2027-2032) Table 65. Agios Company Information Table 66. Agios Business Overview Table 67. Agios FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Agios FIC Dual-target Drugs Product Portfolio Table 69. Agios Recent Development Table 70. BMS Company Information Table 71. BMS Business Overview Table 72. BMS FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. BMS FIC Dual-target Drugs Product Portfolio Table 74. BMS Recent Development Table 75. Boehringer Ingelheim Company Information Table 76. Boehringer Ingelheim Business Overview Table 77. Boehringer Ingelheim FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Boehringer Ingelheim FIC Dual-target Drugs Product Portfolio Table 79. Boehringer Ingelheim Recent Development Table 80. Dermavant Sciences Company Information Table 81. Dermavant Sciences Business Overview Table 82. Dermavant Sciences FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Dermavant Sciences FIC Dual-target Drugs Product Portfolio Table 84. Dermavant Sciences Recent Development Table 85. Genentech Company Information Table 86. Genentech Business Overview Table 87. Genentech FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Genentech FIC Dual-target Drugs Product Portfolio Table 89. Genentech Recent Development Table 90. Gilead Company Information Table 91. Gilead Business Overview Table 92. Gilead FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Gilead FIC Dual-target Drugs Product Portfolio Table 94. Gilead Recent Development Table 95. Immunocore Company Information Table 96. Immunocore Business Overview Table 97. Immunocore FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Immunocore FIC Dual-target Drugs Product Portfolio Table 99. Immunocore Recent Development Table 100. ImmunoGen Company Information Table 101. ImmunoGen Business Overview Table 102. ImmunoGen FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. ImmunoGen FIC Dual-target Drugs Product Portfolio Table 104. ImmunoGen Recent Development Table 105. Mallinckrodt Company Information Table 106. Mallinckrodt Business Overview Table 107. Mallinckrodt FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Mallinckrodt FIC Dual-target Drugs Product Portfolio Table 109. Mallinckrodt Recent Development Table 110. Marinus Company Information Table 111. Marinus Business Overview Table 112. Marinus FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Marinus FIC Dual-target Drugs Product Portfolio Table 114. Marinus Recent Development Table 115. Phathom Company Information Table 116. Phathom Business Overview Table 117. Phathom FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Phathom FIC Dual-target Drugs Product Portfolio Table 119. Phathom Recent Development Table 120. Polarean lmaging Company Information Table 121. Polarean lmaging Business Overview Table 122. Polarean lmaging FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Polarean lmaging FIC Dual-target Drugs Product Portfolio Table 124. Polarean lmaging Recent Development Table 125. Pfizer Company Information Table 126. Pfizer Business Overview Table 127. Pfizer FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Pfizer FIC Dual-target Drugs Product Portfolio Table 129. Pfizer Recent Development Table 130. Eli Lilly Company Information Table 131. Eli Lilly Business Overview Table 132. Eli Lilly FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Eli Lilly FIC Dual-target Drugs Product Portfolio Table 134. Eli Lilly Recent Development Table 135. Roche Company Information Table 136. Roche Business Overview Table 137. Roche FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Roche FIC Dual-target Drugs Product Portfolio Table 139. Roche Recent Development Table 140. Merck Company Information Table 141. Merck Business Overview Table 142. Merck FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Merck FIC Dual-target Drugs Product Portfolio Table 144. Merck Recent Development Table 145. Novartis Company Information Table 146. Novartis Business Overview Table 147. Novartis FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Novartis FIC Dual-target Drugs Product Portfolio Table 149. Novartis Recent Development Table 150. Johnson & Johnson Company Information Table 151. Johnson & Johnson Business Overview Table 152. Johnson & Johnson FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Johnson & Johnson FIC Dual-target Drugs Product Portfolio Table 154. Johnson & Johnson Recent Development Table 155. Sanofi Company Information Table 156. Sanofi Business Overview Table 157. Sanofi FIC Dual-target Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Sanofi FIC Dual-target Drugs Product Portfolio Table 159. Sanofi Recent Development Table 160. Key Raw Materials Table 161. Raw Materials Key Suppliers Table 162. FIC Dual-target Drugs Distributors List Table 163. FIC Dual-target Drugs Customers List Table 164. Research Programs/Design for This Report Table 165. Authors List of This Report Table 166. Secondary Sources Table 167. Primary Sources List of Figures Figure 1. FIC Dual-target Drugs Product Image Figure 2. Global FIC Dual-target Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global FIC Dual-target Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global FIC Dual-target Drugs Sales (2021-2032) & (K Units) Figure 5. Global FIC Dual-target Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 FIC Dual-target Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Polθ/PARP Targets Image Figure 9. GPX4/CDK Targets Image Figure 10. EZH2/HSP90 Targets Image Figure 11. Others Image Figure 12. Global FIC Dual-target Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global FIC Dual-target Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global FIC Dual-target Drugs Sales Market Share by Type (2021-2032) Figure 15. Global FIC Dual-target Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global FIC Dual-target Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global FIC Dual-target Drugs Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Other Image Figure 21. Global FIC Dual-target Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global FIC Dual-target Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global FIC Dual-target Drugs Sales Market Share by Application (2021-2032) Figure 24. Global FIC Dual-target Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global FIC Dual-target Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global FIC Dual-target Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America FIC Dual-target Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe FIC Dual-target Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific FIC Dual-target Drugs Sales Market Share by Country (2021-2032) Figure 41. China FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa FIC Dual-target Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile FIC Dual-target Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global FIC Dual-target Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global FIC Dual-target Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America FIC Dual-target Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe FIC Dual-target Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific FIC Dual-target Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa FIC Dual-target Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. FIC Dual-target Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. FIC Dual-target Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Polθ/PARP Targets
  • GPX4/CDK Targets
  • EZH2/HSP90 Targets
  • Others
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Agios
  • BMS
  • Boehringer Ingelheim
  • Dermavant Sciences
  • Genentech
  • Gilead
  • Immunocore
  • ImmunoGen
  • Mallinckrodt
  • Marinus
  • Phathom
  • Polarean lmaging
  • Pfizer
  • Eli Lilly
  • Roche
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global FIC Dual-target Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global FIC Dual-target Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global FIC Dual-target Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global FIC Dual-target Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global FIC Dual-target Drugs Market Dynamics
  1. 2.1 FIC Dual-target Drugs Industry Trends
  2. 2.2 FIC Dual-target Drugs Industry Drivers
  3. 2.3 FIC Dual-target Drugs Industry Opportunities and Challenges
  4. 2.4 FIC Dual-target Drugs Industry Restraints
3 FIC Dual-target Drugs Market by Manufacturers
  1. 3.1 Global FIC Dual-target Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global FIC Dual-target Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global FIC Dual-target Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global FIC Dual-target Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global FIC Dual-target Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global FIC Dual-target Drugs Manufacturers, Product Type & Application
  7. 3.7 Global FIC Dual-target Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global FIC Dual-target Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 FIC Dual-target Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 FIC Dual-target Drugs Tier 1, Tier 2, and Tier 3
4 FIC Dual-target Drugs Market by Type
  1. 4.1 FIC Dual-target Drugs Type Introduction
  2. 4.1.1 Polθ/PARP Targets
  3. 4.1.2 GPX4/CDK Targets
  4. 4.1.3 EZH2/HSP90 Targets
  5. 4.1.4 Others
  6. 4.2 Global FIC Dual-target Drugs Sales by Type
  7. 4.2.1 Global FIC Dual-target Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global FIC Dual-target Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global FIC Dual-target Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global FIC Dual-target Drugs Revenue by Type
  11. 4.3.1 Global FIC Dual-target Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global FIC Dual-target Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global FIC Dual-target Drugs Revenue Market Share by Type (2021-2032)
5 FIC Dual-target Drugs Market by Application
  1. 5.1 FIC Dual-target Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global FIC Dual-target Drugs Sales by Application
  6. 5.2.1 Global FIC Dual-target Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global FIC Dual-target Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global FIC Dual-target Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global FIC Dual-target Drugs Revenue by Application
  10. 5.3.1 Global FIC Dual-target Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global FIC Dual-target Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global FIC Dual-target Drugs Revenue Market Share by Application (2021-2032)
6 Global FIC Dual-target Drugs Sales by Region
  1. 6.1 Global FIC Dual-target Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global FIC Dual-target Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global FIC Dual-target Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global FIC Dual-target Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America FIC Dual-target Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America FIC Dual-target Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe FIC Dual-target Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe FIC Dual-target Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific FIC Dual-target Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific FIC Dual-target Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa FIC Dual-target Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa FIC Dual-target Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global FIC Dual-target Drugs Revenue by Region
  1. 7.1 Global FIC Dual-target Drugs Revenue by Region
  2. 7.1.1 Global FIC Dual-target Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global FIC Dual-target Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global FIC Dual-target Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global FIC Dual-target Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America FIC Dual-target Drugs Revenue (2021-2032)
  8. 7.2.2 North America FIC Dual-target Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe FIC Dual-target Drugs Revenue (2021-2032)
  11. 7.3.2 Europe FIC Dual-target Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific FIC Dual-target Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific FIC Dual-target Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa FIC Dual-target Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa FIC Dual-target Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Agios
  2. 8.1.1 Agios Company Information
  3. 8.1.2 Agios Business Overview
  4. 8.1.3 Agios FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Agios FIC Dual-target Drugs Product Portfolio
  6. 8.1.5 Agios Recent Developments
  7. 8.2 BMS
  8. 8.2.1 BMS Company Information
  9. 8.2.2 BMS Business Overview
  10. 8.2.3 BMS FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BMS FIC Dual-target Drugs Product Portfolio
  12. 8.2.5 BMS Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim FIC Dual-target Drugs Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Dermavant Sciences
  20. 8.4.1 Dermavant Sciences Company Information
  21. 8.4.2 Dermavant Sciences Business Overview
  22. 8.4.3 Dermavant Sciences FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Dermavant Sciences FIC Dual-target Drugs Product Portfolio
  24. 8.4.5 Dermavant Sciences Recent Developments
  25. 8.5 Genentech
  26. 8.5.1 Genentech Company Information
  27. 8.5.2 Genentech Business Overview
  28. 8.5.3 Genentech FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Genentech FIC Dual-target Drugs Product Portfolio
  30. 8.5.5 Genentech Recent Developments
  31. 8.6 Gilead
  32. 8.6.1 Gilead Company Information
  33. 8.6.2 Gilead Business Overview
  34. 8.6.3 Gilead FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Gilead FIC Dual-target Drugs Product Portfolio
  36. 8.6.5 Gilead Recent Developments
  37. 8.7 Immunocore
  38. 8.7.1 Immunocore Company Information
  39. 8.7.2 Immunocore Business Overview
  40. 8.7.3 Immunocore FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Immunocore FIC Dual-target Drugs Product Portfolio
  42. 8.7.5 Immunocore Recent Developments
  43. 8.8 ImmunoGen
  44. 8.8.1 ImmunoGen Company Information
  45. 8.8.2 ImmunoGen Business Overview
  46. 8.8.3 ImmunoGen FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ImmunoGen FIC Dual-target Drugs Product Portfolio
  48. 8.8.5 ImmunoGen Recent Developments
  49. 8.9 Mallinckrodt
  50. 8.9.1 Mallinckrodt Company Information
  51. 8.9.2 Mallinckrodt Business Overview
  52. 8.9.3 Mallinckrodt FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mallinckrodt FIC Dual-target Drugs Product Portfolio
  54. 8.9.5 Mallinckrodt Recent Developments
  55. 8.10 Marinus
  56. 8.10.1 Marinus Company Information
  57. 8.10.2 Marinus Business Overview
  58. 8.10.3 Marinus FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Marinus FIC Dual-target Drugs Product Portfolio
  60. 8.10.5 Marinus Recent Developments
  61. 8.11 Phathom
  62. 8.11.1 Phathom Company Information
  63. 8.11.2 Phathom Business Overview
  64. 8.11.3 Phathom FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Phathom FIC Dual-target Drugs Product Portfolio
  66. 8.11.5 Phathom Recent Developments
  67. 8.12 Polarean lmaging
  68. 8.12.1 Polarean lmaging Company Information
  69. 8.12.2 Polarean lmaging Business Overview
  70. 8.12.3 Polarean lmaging FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Polarean lmaging FIC Dual-target Drugs Product Portfolio
  72. 8.12.5 Polarean lmaging Recent Developments
  73. 8.13 Pfizer
  74. 8.13.1 Pfizer Company Information
  75. 8.13.2 Pfizer Business Overview
  76. 8.13.3 Pfizer FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer FIC Dual-target Drugs Product Portfolio
  78. 8.13.5 Pfizer Recent Developments
  79. 8.14 Eli Lilly
  80. 8.14.1 Eli Lilly Company Information
  81. 8.14.2 Eli Lilly Business Overview
  82. 8.14.3 Eli Lilly FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Eli Lilly FIC Dual-target Drugs Product Portfolio
  84. 8.14.5 Eli Lilly Recent Developments
  85. 8.15 Roche
  86. 8.15.1 Roche Company Information
  87. 8.15.2 Roche Business Overview
  88. 8.15.3 Roche FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Roche FIC Dual-target Drugs Product Portfolio
  90. 8.15.5 Roche Recent Developments
  91. 8.16 Merck
  92. 8.16.1 Merck Company Information
  93. 8.16.2 Merck Business Overview
  94. 8.16.3 Merck FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Merck FIC Dual-target Drugs Product Portfolio
  96. 8.16.5 Merck Recent Developments
  97. 8.17 Novartis
  98. 8.17.1 Novartis Company Information
  99. 8.17.2 Novartis Business Overview
  100. 8.17.3 Novartis FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Novartis FIC Dual-target Drugs Product Portfolio
  102. 8.17.5 Novartis Recent Developments
  103. 8.18 Johnson & Johnson
  104. 8.18.1 Johnson & Johnson Company Information
  105. 8.18.2 Johnson & Johnson Business Overview
  106. 8.18.3 Johnson & Johnson FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Johnson & Johnson FIC Dual-target Drugs Product Portfolio
  108. 8.18.5 Johnson & Johnson Recent Developments
  109. 8.19 Sanofi
  110. 8.19.1 Sanofi Company Information
  111. 8.19.2 Sanofi Business Overview
  112. 8.19.3 Sanofi FIC Dual-target Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Sanofi FIC Dual-target Drugs Product Portfolio
  114. 8.19.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 FIC Dual-target Drugs Value Chain Analysis
  2. 9.1.1 FIC Dual-target Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 FIC Dual-target Drugs Production Mode & Process
  6. 9.2 FIC Dual-target Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 FIC Dual-target Drugs Distributors
  9. 9.2.3 FIC Dual-target Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst